Showing posts with label medicine. Show all posts
Showing posts with label medicine. Show all posts

Wednesday, July 9, 2008

050: Discovery of key malaria proteins could mean sticky end for parasite

Life Science Space (June 9, 2008)--Scientists funded by the Wellcome Trust have identified a key mechanism that enables malaria-infected red blood cells to stick to the walls of blood vessels and avoid being destroyed by the body's immune system. The research, published today in the journal Cell, highlights an important potential new target for anti-malarial drugs.




a map where is malaria found (Image credit: www.malariahotspots.co.uk)

Malaria is one of the world's biggest killers, killing over a million people every year, mainly children and pregnant women in Africa and south east Asia. It is caused by the malaria parasite, which is injected into the bloodstream from the salivary glands of infected mosquitoes. There are a number of different species of parasite, but the deadliest is the Plasmodium falciparum parasite, which accounts for 90% of deaths from malaria.

The malaria parasite infects healthy red blood cells, where it reproduces, producing up to thirty-two new daughter parasites. The parasite secretes a "glue", known as PfEMP1, which travels to the surface of the infected red blood cells, leading to the formation of the knobs on the surface of the cells. The cells become sticky and adhere to the walls of the blood vessels. This prevents the cells being flushed through the spleen, where the parasites would be destroyed by the body's immune system, but also restricts blood supply to vital organs.


Plasmodium falciparum: Blood Stage Parasites: Thin Blood Smears

(CDC Illustrations from: Coatney GR, Collins WE, Warren M, Contacos PG. The Primate Malarias. U.S. Department of Health, Education and Welfare, Bethesda, 1971)

Now, an international collaboration of scientists has identified eight new proteins that transport the P. falciparum parasite's "glue" to the surface of the infected red blood cells. The researchers, led by Professor Alan Cowman from the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, have shown that removing just one of these proteins prevents the infected red blood cells from sticking to the walls of the blood vessels.

"These findings greatly enhance our understanding of how the malaria parasite commandeers the red blood cell for its own survival and avoids our immune defences," says Professor Cowman. "They also suggest that a drug that targets the 'stickiness' proteins could be an effective treatment for malaria."

Malaria is currently treated using drugs that kill the parasites. However, as the parasites evolve, they have become increasingly resistant to existing treatments such as chloroquine and mefloquine, and there is some evidence of increasing resistance against even the most effect and newest treatments, artemisinin derivatives such as artesunate.

"Malaria parasites are evolving, making our current treatments increasingly less effective," says Professor Alister Craig from the Liverpool School of Tropical Medicine, who collaborated on the project. "This suggests we need to approach the problem using a different strategy. A drug which prevents disease rather than killing the parasite might be important because it could retain natural inoculation in the patient, limiting damage caused by the parasite and providing protection from further infection."

The research was carried out by interfering with the function of specific genes on a scale not previously attempted in the malaria parasite. By blocking or "knocking out" the function of these genes the team was able to identify those important for allowing the parasite to stick to the walls of blood vessels.

The work was funded by the Wellcome Trust through its Functional Genomics Development Initiative and builds on earlier work by the Malaria Genome Project, which sequenced the genome of the P. falciparum parasite.

-----------------------------------------------------------------------

Tuesday, July 8, 2008

049: Herbal Remedy Reduces Obesity And Heart Disease?

Life Science Space (July 8, 2008)--With unprecedented levels of obesity across the Western world, and incidence of associated heart disease, cancer and diabetes rising, there is a major drive to find new treatments. Scientists from Germany have recently discovered that extracts of a traditional herbal remedy derived from Tabebuia impetiginosa can act to delay the absorption of dietary fat in animal models.
Tabebuia impetiginosa, commonly known as Pink IpĂȘ, is a deciduous tree, native to Central and South America, and is related to magnolias.

They believe that the extract could be incorporated into a food supplement which may not only reduce obesity, but also lessen the risk of development of type 2 diabetes and coronary heart disease. Dr Nils Roos from the Max Rubner Institute will present the results on July 7th at the Society for Experimental Biology's Annual Meeting in Marseille.

Dr Roos and his team have shown that Tabebuia extract can reduce levels of triglycerides, a breakdown product of fat, in rats after they have been fed a fatty meal. "This result shows the extract may have a potential use in treating obesity," he observes.

"However, as coronary heart disease and diabetes have also been shown to be associated with higher triglyceride levels after eating, we believe a food-supplement based on Tabebuia could reduce the incidence of these diseases as well. What is more, as obesity in developing countries is also on the increase, such extracts, taken as a capsule or added to food, may be a cheaper alternative for the rural population to pharmaceuticals, he continued."

Although it is clear that Tabebuia extract can act to inhibit the absorption of dietary fat, the scientists have not yet identified the exact compounds within the extract that are responsible for the effects. "The actual substances involved are probably even more active than the extract," says Dr Roos. "We are currently in the process of identifying these compounds, and will then test long-term efficiacy and safety in miniature pigs whose physiology is closer to that of humans than rat physiology is, before moving onto human trials. At this point, we hope to be able to develop the extract, either as a food supplement or in a medicinal context.

---------------------------------------------------------------------

Source: http://www.eurekalert.org/pub_releases/2008-07/sfeb-hrr070408.php

Monday, June 30, 2008

044: New UGA invention effectively kills foodborne pathogens in minutes

Life Science Space (June 30, 2008)--University of Georgia researchers have developed an effective technology for reducing contamination of dangerous bacteria on food. The new antimicrobial wash rapidly kills Salmonella and E. coli O157:H7 on foods ranging from fragile lettuce to tomatoes, fruits, poultry products and meats. It is made from inexpensive and readily available ingredients that are recognized as safe by the U.S. Food and Drug Administration.
The new technology, which has commercial application for the produce, poultry, meat and egg processing industries, is available for licensing from the University of Georgia Research Foundation, Inc., which has filed a patent application on the new technology.

The Centers for Disease Control and Prevention estimates that, in the U.S. alone, foodborne pathogens are responsible for 76 million illnesses every year. Of the people affected by those illnesses, 300,000 are hospitalized and more than 5,000 die. These widespread outbreaks of food-borne illnesses are attributed, in part, to the fast-paced distribution of foods across the nation. Recently, raw tomatoes caused an outbreak of salmonellosis that sickened more than 300 people in at least 28 states and Canada.

Currently, a chlorine wash is frequently used in a variety of ways to reduce harmful bacteria levels on vegetables, fruits and poultry, but because of chlorine’s sensitivity to food components and extraneous materials released in chlorinated water treatments, many bacteria survive. Chlorine is toxic at high concentrations, may produce off-flavors and undesirable appearance of certain food products, and it can only be used in conjunction with specialized equipment and trained personnel. In addition, chlorine may be harmful to the environment.

“We can’t rely on chlorine to eliminate pathogens on foods,” said Michael Doyle, one of the new technology’s inventors and director of UGA’s Center for Food Safety. “This new technology is effective, safe for consumers and food processing plant workers, and does not affect the appearance or quality of the product. It may actually extend the shelf-life of some types of produce.”

Doyle is an internationally recognized authority on food safety whose research focuses on developing methods to detect and control food-borne bacterial pathogens at all levels of the food continuum, from the farm to the table. He has served as a scientific advisor to many groups, including the World Health Organization, the Food and Drug Administration, the U.S. Department of Agriculture, the U.S. Department of Defense and the U.S. Environmental Protection Agency.

The new antimicrobial technology, developed by Doyle and Center for Food Safety researcher Tong Zhao, uses a combination of ingredients that kills bacteria within one to five minutes from application. It can be used as a spray and immersion solution, and its concentration can be adjusted for treatment of fragile foods such as leafy produce, more robust foods such as poultry, or food preparation equipment and food transportation vehicles.

“The effectiveness, easy storage and application, and low cost of this novel antibacterial make it applicable not only at food processing facilities, but also at points-of-sale and at home, restaurants and military bases. The development of this technology is timely, given the recent, sequential outbreaks of foodborne pathogens,” said Gennaro Gama, UGARF technology manager in charge of licensing this technology.
--------------------------------------------------------------------------------
New release. University of Georgia.

Tuesday, June 17, 2008

034: Coffee Drinkers Might Live Longer

Life Science Space (June 17, 2008)--Good news for coffee lovers: Drinking up to six cups a day of caffeinated or decaffeinated coffee daily won't shorten your life span, a new study shows.

In fact, coffee might even help the heart, especially for women, the researchers found.

"Our results suggest that long-term, regular coffee consumption does not increase the risk of death and probably has several beneficial effects on health," said lead researcher Dr. Esther Lopez-Garcia, assistant professor of preventive medicine at the Autonoma University in Madrid, Spain. Her team published its findings in the June 17 issue of the Annals of Internal Medicine.
Lopez-Garcia stressed that the findings may only hold true only for healthy folk. "People with any disease or condition should ask their doctor about their risk, because caffeine still has an acute effect on short-term increase of blood pressure," she said.

In the study, the Spanish team looked at the relationships between coffee drinking and the risks of dying from heart disease, cancer, or any cause in almost 42,000 men who participated in the Health Professionals Follow-Up Study and more than 84,000 women who had participated in the Nurses' Health Study. At the study start, all participants were free of heart disease and cancer.

The participants completed questionnaires every two to four years, including information about their coffee drinking, other dietary habits, smoking and health conditions. The research team looked at the frequency of death from any cause, death due to heart disease, and death due to cancer among people with different coffee-drinking habits, comparing them to those who didn't drink the brew. They also controlled for other risk factors, including diet, smoking and body size.

The researchers found that women who drank two or three cups of caffeinated coffee daily had a 25 percent lower risk of death from heart disease during the follow-up (from 1980 to 2004) than non-drinkers. Women also had an 18 percent lower death risk from a cause other than cancer or heart disease compared with non-coffee drinkers.

For men, drinking two to three cups of caffeinated coffee daily was a "wash" -- not associated with either an increased or a decreased risk of death during the follow up, from 1986 to 2004.

The lower death rate was mainly due to a lower risk for heart disease deaths, the researchers found, while no link was discovered for coffee drinking and cancer deaths. The relationship did not seem to be directly related to caffeine, according to the researchers, since those who drank decaf also had a lower death rate than those who didn't drink either kind of coffee.

In the past, studies have come up with mixed results on the health effects of coffee, with some finding coffee increased the risk of death and others not.

More recently, research has found coffee drinking linked with a lower risk of type 2 diabetes and some cancers, and preventing the development of cardiovascular disease, Lopez-Garcia said.

The strength of her current study, she said, includes the large number of participants and long follow-up period.
While the study is interesting, it does have its shortcomings, said Dr. Peter Galier, an internal medicine specialist, former chief of staff at Santa Monica UCLA and Orthopedic Hospital and associate professor of medicine at the University of California Los Angeles' David Geffen School of Medicine.

Self-reporting is one shortcoming, he said, because people may have under- or over-reported their coffee consumption, for instance.

"I think what this study tells us is not so much that coffee is the answer to everything," he said. But, rather, that some compounds, such as the antioxidants found in coffee, may be healthy.

Galier's advice for consumers: "I would tell them to weigh the subjective risk of their coffee consumption," he said. For instance, "if they love coffee, but it makes them jittery, and they can't sleep, the need to adjust it," he said. "Look at your symptoms," he tells patients. "If decaf is no problem, I wouldn't put a limit on that."

The research was funded by grants from the U.S. National Institutes of Health.
----------------------------------------------------------------------
Source:

033: Biomarker may help pinpoint prostate cancer recurrence

Life Science Space (June 17, 2008)--A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.

Prostate cancer cells with fluorescently labeled cancer cells (red). (Image Credit: MIT Press Office and Benjamin A. Teply)


In a study published in the June 15 issue of Clinical Cancer Research, UT Southwestern scientists identified a panel of seven biomarkers that can predict with 86 percent accuracy which prostate cancer patients will experience a recurrence and progression of the disease. Biomarkers are proteins circulating in a patient’s blood that are specific to a disease.

Current risk assessment methods, which include stage and grade of cancer and the level of prostate-specific antigen, can predict prostate cancer recurrence with about 70 percent accuracy.

“There are several unresolved issues in the clinical and surgical management of prostate cancer, one of them being the identification of men who have insignificant cancers and can be followed, and another being the identification of men most likely to have spread of disease and early or late recurrence,” said Dr. Claus Roehrborn, chairman of urology at UT Southwestern and one of the study’s authors. “In the future, once we can reliably identify those patients, we may be able to offer additional treatment to counteract that risk and give those men a better chance for a permanent cure. The panel of biomarkers is an important step in this direction.”

Drs. Claus Roehrborn (right), chairman of urology, and Shahrokh Shariat have identified seven biomarkers that may help pinpoint prostate cancer recurrence.(Image Credit: UT Southwestern Medical Center)


For nine years, Dr. Shahrokh Shariat, who is now a resident in urology at UT Southwestern and the study’s lead author, has been collaborating with basic-science researchers and clinicians to find a comprehensive group of biomarkers associated with prostate cancer that could more accurately predict the biological behavior of the disease.

Using commonly available blood testing methods, Dr. Shariat and his team measured the levels of seven biomarkers in 423 patients who were subsequently surgically treated with a radical prostatectomy and bilateral lymphadenectomy.

Of the study participants, 75 had a recurrence of their cancer. All 75 had elevated levels of at least several of the seven biomarkers. Dr. Shariat’s seven-biomarker model was able to accurately predict the risk for recurrence 86.6 percent of the time.

“We found that a combination of independent yet complementary markers may provide a more accurate prediction outcome compared to single markers,” Dr. Shariat said. “This could help physicians provide individualized care and targeted therapy for patients. It will also allow us to design clinical trials to target these individual biomarkers.”

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the United States. Although prostate-removal surgery and radiation therapy have been successful in controlling the disease, up to 40 percent of patients experience a relapse.

“A prediction tool based on the biomarkers we tested could improve the accuracy of standard models and help doctors counsel patients better about their risk for prostate cancer recurrence and help to determine the course of treatment,” Dr. Shariat said. “There is no doubt that we are approaching a time when use of proper biomarkers will help detect, monitor and manage the progression of this disease, as well as assist with therapeutic decisions.”

The next step is to explore the role of these biomarkers in patients treated with other therapies, such as radiation, and patients with a different range of disease severity.

Currently, the seven-biomarker panel is being externally validated in a clinical trial at two medical institutions, one in the United States and the other in Europe.

Dr. Jose Karam, a resident in urology at UT Southwestern, was also involved in the study.

An international team of researchers from the University of Montreal; Vita-Salute University in Milan, Italy; and Baylor College of Medicine contributed to the research.

---------------------------------------------------------------------
Source: UT Soutwestern new release: http://www.utsouthwestern.edu/utsw/cda/dept37389/files/468245.html

Learn more about prostate cancer @Prostate Cancer In-Depth Report, NYTimes.com: http://health.nytimes.com/health/guides/disease/prostate-cancer/print.html

Monday, June 16, 2008

032: Pencillin, Fermentation & Pfizer

Fermentation tanks at Pfizer’s Marcy Avenue facility in Brooklyn.
Courtesy, Pfizer Inc.

The development of deep-tank fermentation by Pfizer —– which enabled the mass production of penicillin for use in World War II —– was designated a National Historic Chemical Landmark by the American Chemical Society (ACS) in a special ceremony in Brooklyn, N.Y., on June 12, 2008.

Thomas H. Lane, Ph.D., president-elect of the Society, presented a commemorative plaque to Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer Inc. “The ACS has recognized only 61 chemical landmarks since the inception of the program in 1993,” said Dr. Lane, who is Director, Global Science and Technology Outreach and Senior Research Scientist, at Dow Corning Corporation. “This makes the award to Pfizer a mark of distinction for contributions that reach far beyond the boundaries of scientific practitioners, touching many lives over many decades.”

“We are proud to receive this designation, which honors the company’s heritage of finding unique answers to new challenges,” Mr. Kindler said. “Charles Pfizer and Company began nearly 160 years ago as a family-owned business right here in Brooklyn, and the breakthroughs recognized by this award reflect the spirit of innovation and the commitment to patients for which Pfizer is now known worldwide.”

Though penicillin was discovered by Alexander Fleming in England in 1928, he couldn’t figure out a way to produce enough for medical use, and penicillin remained nothing more than a laboratory curiosity. In the late 1930s, with the onset of World War II, scientists saw potential to resurrect Fleming's work to make a germ-killing medicine to save the lives of Allied soldiers. In 1941 the U. S. and British governments issued a challenge to the American pharmaceutical industry: Develop a way to mass produce penicillin to help the soldiers.

Each company chose a different method. Charles Pfizer & Co. —– a relatively small chemical company based in Brooklyn —– gambled on fermentation, drawing from the unique expertise it developed 20 years earlier to mass produce citric acid.

Citric acid is a key ingredient in foods and beverages —– notably soft drinks. It is a natural preservative that adds a pleasantly acidic or sour taste. Charles Pfizer & Co had made citric acid the traditional way since 1880: from unripe citrus fruit, mainly imported from Italy, but World War I interfered with the supply. In 1917 Pfizer hired James Currie, a food chemist, who had the daring idea of producing citric acid without using citrus. Currie knew that fermentation of a fungus, or mold, called Aspergillis niger could convert sugar into citric acid. Currie also understood that Aspergillis niger is aerobic, meaning it needs air to grow.

Aided by Jasper Kane, his precocious 16-year-old laboratory assistant from Brooklyn, Currie tried to grow the mold in a large flat pan purchased at the five-and-ten, but had limited success. He cut the pan into smaller, shallower pans, and immediately increased the yield. Still, the process was unpredictable and subject to a number of difficult variables: The quality of the mold spores, the purity of the cultures, contamination of air and the medium, humidity and temperature, and many others.

Currie plugged on, and in 1919 Pfizer opened a pilot plant using his fermentation process, named SUCIAC —“Sugar Under Conversion to Citric Acid.” By the mid-1920s the output of citric acid using fermentation far outpaced the production from lemons and limes. The price of citric acid, $1.25 a pound in 1919, dropped to 20 cents.

Pfizer began applying fermentation to other products, such as gluconic acid (used as a food preservative and cleanser) and ascorbic acid (Vitamin C), and experimented with innovative technologies to increase the yields. Eventually the company began to use a fermentation process in deep tanks rather than shallow pans and flasks.

Pfizer’s technological advances in using deep tanks for fermentation proved critical when Allied governments sent out the call for penicillin. Initially, Pfizer researchers, led by Jasper Kane, used shallow flasks and pans like those that were used for citric acid, and they made gradual progress in improving penicillin’s potency and purity. The breakthrough came when Kane suggested a different approach: the deep-tank method that proved successful for gluconic acid. They needed huge tanks that could hold thousands of gallons of “fermentation liquor.” Pfizer purchased an old ice plant in Brooklyn that had the necessary refrigeration equipment and converted it into a penicillin factory which opened on March 1, 1944.

The plant contained fourteen 7,500-gallon tanks and soon the company was producing more penicillin in one month than it had in all of 1943. Most of the penicillin that went ashore with Allied forces on D-Day came from Pfizer’s Brooklyn facility.

After World War II, Pfizer applied its deep-tank fermentation to manufacture streptomycin, an important antibiotic discovered by Dr. Selman Waksman and colleagues at Rutgers, and then to Terramycin®, the first antibiotic developed exclusively by the company’s scientists. Terramycin, which proved effective against a wide range of deadly bacteria, was developed from a microorganism in soil from the American Midwest (“Terramycin” is derived from the Latin for “earth fungus”).

--------------------------------------------------------------------
Source:
Pfizer’s work on penicillin for World War II becomes a National Historic Chemical Landmark. American Chemical Society

031: Novel compound may treat acute diarrhea

Life Science Space (June 16, 2008)--Debilitating Illness Is Major Cause of Child Deaths in Developing Nations

There are 1.9 million deaths a year in children (globally) under 5 every year due to diarrheal diseases. According to WHO, about two-thirds of these (1.3 million) occur in the 15 countries in Asia and Africa.(Image Credit: Time.com)

In a development that may lessen the epidemic of diarrhea-related deaths among children in developing countries, scientists in the laboratory of Nobel Laureate Ferid Murad, M.D., Ph.D., at The University of Texas Health Science Center at Houston have discovered a novel compound that might lead to an inexpensive, easy-to-take treatment. The results of pre-clinical tests appear in the June 16 online edition of the journal Proceedings of the National Academy of Sciences of the United States of America

The compound - a pyridopyrimidine derivative - targets acute secretory diarrhea caused by E. coli and other enterotoxigenic strains of bacteria, which produce toxins that stimulate the linings of the intestines, causing them to secrete excessive fluid, thereby producing diarrhea

Diarrhea kills an estimated 1.6 to 2.5 million children every year, according to researchers quoted in the Bulletin of the World Health Organization. Enterotoxigenic strains of bacteria may account for a significant amount of these deaths, according to an article in Clinical Microbiology Reviews. Enterotoxigenic E. coli or ETEC is a leading cause of bacterial diarrhea.

During pre-clinical tests, the compound was associated with a significant reduction in intestinal fluid secretion in an animal model of bacterial diarrhea. It was also linked to reduced fluid build up during laboratory tests on human colon cells. It caused significant decrease in fluid secretion without apparent toxicity.

This unique approach to the treatment of enterotoxigenic diarrhea works by interrupting the diarrhea-causing chain of events that occur when bacterial toxins enter the intestinal tract. The compound slows the transmission of information in the epithelial cells lining the intestines. Consequently, the molecular mediators regulating the secretion of salt and fluid in the gut do not get fully activated. ETEC comes from feces-contaminated food or water and also causes travelers’ diarrhea.

“This newly discovered compound decreases the formation of ever-present cellular messenger molecules, cyclic guanosine monophosphate and cyclic adenosine monophosphate, caused by various bacterial toxins and might prevent or attenuate the intestinal fluid secretion, diarrhea and dehydration,” said Murad, the senior author. “While this research looks extremely promising as a preventive or therapeutic intervention in Third World diarrheal disease and travelers’ diarrhea, much work remains to be done to move into clinical trials and eventual therapeutic approval.”

In the event of an earthquake, typhoon or other catastrophe, this potential diarrhea treatment could be used to treat outbreaks of enterotoxigenic E. coli caused by contaminated food and water supplies, Murad said. The compound can be placed in a pill for adults and in a liquid for children.

Secretory diarrhea describes the condition when the small intestine, which is normally an absorptive organ, is stimulated to secrete salts and water into the intestinal lumen, often in massive quantities. The resulting diarrhea can lead to profound fluid loss, dehydration, shock and death.

There are many causes of secretory diarrhea. The most common, by far, is infestation of the small intestine by certain bacteria, such as cholera or certain strains of E. coli, following ingestion of contaminated water or food. These bacteria multiply in the intestinal tract and produce toxins that bring about elevations of a group of intracellular messengers, cyclic nucleotides, that stimulate intestinal cells to secrete salt and water.

To date, there is no effective way of treating these diarrheas directly. Treatment is indirect and aimed at preventing serious outcomes by minimizing fluid loss using intravenous or, more recently, oral rehydration.
“Dr. Murad and his coworkers have discovered a relatively simple compound that indirectly inhibits the ability of several bacterial toxins to elevate intracellular levels of cyclic nucleotides, and inhibits fluid secretion by animal small intestine exposed to these toxins,” said Stanley G. Schultz, M.D., professor, associate dean for Institutional Advancement and Fondren Chair in Cellular Signaling at The University of Texas Medical School at Houston.

“These findings are a promising lead into what could prove to be a triumph of translational research of staggering importance,” Schultz said. “An inexpensive drug that could block the intestinal secretory pathway, with minimal side effects, would be a “magic bullet” that would not only save millions of lives in many parts of the developing world, but would also save the billions of dollars that are lost annually because of diarrhea throughout the world. It would truly be a treatment of diarrhea rather than a treatment of the consequences of diarrhea.” Schultz received the 2006 Prince Mahidol Award for Medicine for pioneering research that led to the development of oral rehydration therapy.

Herbert L. DuPont, M.D., professor of infectious diseases and director of the Center For Infectious Diseases at The University of Texas School of Public Health, said, “The approach being taken here is to decrease fluid loss from the intestine, which is directed to the most important body mechanism leading to acute diarrhea.”

“Current antidiarrheal therapy is less physiologic, often working through inhibition of intestinal movement leading to potential complications. A drug that stops the loss of fluid and salt from the intestine could save infant lives in developing regions and alleviate suffering that would otherwise be experienced by travelers to the tropics and subtropics,” DuPont said.

Travelers’ diarrhea affects millions of people annually. The promising treatment is the result of a 30-year investigation by Murad and long-time colleague Richard L. Guerrant, M.D., director of the Center for Global Health at the University of Virginia School of Medicine, Charlottesville, into the molecular mechanisms of ETEC, which began with the identification of a link between the messenger molecules and a bacterial strain of diarrhea pathogen from Bangladesh.

Murad credits advances in biochemistry with their discovery. “I always thought we would find a compound. We now have the right set of people and right circumstances to solve this. We found this compound while screening a library of chemical substances,” Murad said.

This area of molecular medicine is called cell signaling “You start with one molecule of a toxin or a hormone,” said Alexander Kots, Ph.D., the lead author and an instructor at the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), a part of the UT Health Science Center at Houston. “The toxin binds to a target and influences it. Soon you have 10 molecules, then 100, then 1,000 and so forth. This is called signal amplification. One molecule of toxin can produce millions of molecules of water.”

Their strategy is to stop the signal amplification process early on, thereby halting enterotoxigenic diarrhea, said co-author Byung-Kwon Choi, Ph.D., a research fellow at the IMM.

“Various bacterial toxins are responsible for increasing the production of intracellular messenger molecules. These molecules contribute to the increase in fluid secretion. We discovered a compound that blocks one of the pathways responsible for ETEC diarrhea. This has never been done before,” Murad said.

Besides diarrheal disease, this potential drug, based on its mechanism of action, could have promising effects in other diseases such as inflammatory bowel disease and some endocrine disorders, Murad said.

“The relatively easy chemical synthesis (single step) and a presumed low cost should make it very attractive for therapy of diarrhea in developing countries,” Murad wrote in the paper.



Ferid Murad (Left) earned a Nobel Prize in Medicine in 1998 for the discovery of nitric oxide’s role in cardiovascular disorders. His previous work with nitric oxide led to novel therapies for hypertension, angina, pulmonary hypertension and erectile dysfunction.

An international patent application for the use of this compound to treat secretory diseases is pending.
Financial support for the study was provided by The Welch Foundation, The Dunn Foundation, The National Institutes of Health, the Department of Defense and The University of Texas Health Science Center at Houston.

----------------------------------------------------------------------
Source: News room, the University of Texas--http://publicaffairs.uth.tmc.edu/Media/newsreleases/nr2008/acutediarrhea.htm

Learn more about diarrhea @ Time online--http://www.time.com/time/magazine/article/0,9171,901061016-1543884,00.html


See abstract @ Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea--http://www.pnas.org/cgi/doi/10.1073/pnas.0803096105
See more @
New compound may treat serious bacterial diarrhea.

Thursday, June 12, 2008

029: Researchers identify potential biomarkers of pancreatic cancer

Life Science Space (June 12, 2008)--A multicenter team of researchers has identified a panel of proteins linked to early development of pancreatic cancer in mice that applies also to early stages of the disease in humans — a breakthrough that brings scientists a significant step closer to developing a blood test to detect the disease early, when cure rates are highest.

Findings bring scientists a big step closer to developing a blood test for early detection of cancer (Image Credit: Robert A. Weinberg)

The findings, by senior author Samir "Sam" Hanash, M.D., Ph.D., of Fred Hutchinson Cancer Research Center, will be published in the June 10 issue of PLoS Medicine, a freely available, open-access online journal. Investigators from Massachusetts General Hospital, University of Michigan and Belfer Institute for Innovative Cancer Science at Dana-Farber Cancer Institute collaborated on the research.

"Our team identified, for the first time, protein changes associated with early-stage pancreatic-tumor development in genetically engineered mice that were also found to be associated with the presence of the disease in humans at an early, pre-symptomatic stage," said Hanash, head of the Hutchinson Center's Molecular Diagnostics Program. Hanash is an international leader in the field of proteomics, which seeks to identify clinically relevant trace proteins, or biomarkers, that are leaked by tumors into the blood. Scientists believe that such proteins could be used in screening blood tests for early and more accurate detection of cancer and other diseases.

Proteomics expert Dr. Samir Hanash joined the Public Health Sciences Division faculty last August to launch new early cancer detection studies. (Image Credit: Gordon Todd)

"Our findings represent a breakthrough in the application of advanced proteomic technologies and mouse models to cancer-biomarker discovery," said Hanash, also a member of the Hutchinson Center's Public Health Sciences Division.

The five-biomarker panel, if developed into a commercial screening test, may be particularly useful when combined with a currently available test that measures a pancreatic-cancer biomarker called CA19.9, which is elevated in 80 percent of newly diagnosed patients but is not linked to asymptomatic, early-stage disease.

Together, the biomarker panel and CA19.9 may significantly improve the detection of early-stage disease prior to the onset of symptoms and may also help better distinguish between cancer and pancreatitis, a noncancerous, inflammatory condition.

Early detection of cancer is crucial for long-term survival. Most solid tumors can be cured 90 percent of the time if they're detected and treated early, whereas cure rates for late-stage cancer are about 10 percent. Early detection is particularly relevant to pancreatic cancer, which is the fourth-leading cause of cancer death in the United States, with a five-year survival rate of only 3 percent. Because the disease is asymptomatic in the early stages, most patients are not diagnosed until the cancer has spread beyond the pancreas, which contributes significantly to the poor long-term survival rate.

"There is a substantial challenge in studying the early molecular changes in pancreatic cancer because most patients are diagnosed with advanced-stage disease and so there is a lack of suitable specimens for biomarker discovery," said paper co-author Nabeel Bardeesy, Ph.D., of the Massachusetts General Hospital Cancer Center.

Finding telltale proteins that can signal the earliest stages of cancer development can be like looking for the proverbial needle in a haystack, as blood contains a complex mixture of thousands of proteins. In addition, any two proteins may exist in concentrations more than a million-fold different from one another. "The ones that are likely to be useful for diagnosing cancer are probably the ones that exist at the lower end of the range, which makes them very hard to find with standard methods," Hanash said.

To guide their quest, Hanash and colleagues employed a variety of technologies to identify, measure and analyze blood proteins in mice and man. Since every protein is different, each has the equivalent of a distinguishing molecular "bar code." The goal is to identify protein signatures that are only present in cancer, which may then serve as biomarkers to detect early disease.

A significant boon to biomarker research — and one of the great scientific advances in the past century, according to paper co-author Ronald DePinho, M.D. — has been the incorporation of mouse models into many disciplines of science, including cancer research. "Our ability to now engineer mice with the same mutations that drive specific cancers in humans has provided powerful and accurate model systems to study virtually all aspects of the disease and then translate these new insights into improved prevention, detection and treatment strategies for cancer," said DePinho, director of the Belfer Institute at Dana-Farber Cancer Institute.

For this study, the researchers first analyzed blood samples from genetically engineered mouse models of pancreatic ductal adenocarcinoma at both early and late stages of tumor development. Of nearly 1,500 proteins identified in these mice, five were associated consistently with a precancerous condition known as pancreatic intraepithelial neoplasia, or PanIN, which, if left untreated, eventually progresses to full-blown pancreatic cancer.

The researchers then sought to determine whether the same biomarkers turned up in blood samples obtained from 30 recently diagnosed pancreatic-cancer patients. They also looked for the biomarkers in 13 people with asymptomatic, early-stage pancreatic cancer who had donated blood for another, unrelated study within a year of their cancer diagnosis. For comparison purposes, the researchers analyzed blood from 20 healthy subjects and 15 people diagnosed with chronic pancreatitis.

Next steps in the research will include validating additional candidate biomarkers and further testing of the biomarker panel they have assembled to see how well it distinguishes between pancreatitis and pancreatic cancer. The researchers also want to continue testing the value of a biomarker-panel approach for early detection of pancreatic cancer among those at increased risk, such as people with a strong family history of the disease.

The National Cancer Institute Mouse Models of Human Cancer Program, NCI Early Detection Research Network, National Institutes of Health, Canary Foundation, Paul Allen Foundation, Waxman Foundation, Verville Family Foundation and Deutsche Forschungsgemeinschaft funded the research.

----------------------------------------------------------------------
Source:
http://www.fhcrc.org/about/ne/news/2008/06/09/pancreatic_biomarkers.html

See also:

Potential biomarkers for pancreatic cancer identified-- http://www.eurekalert.org/pub_releases/2008-06/plos-pbf060508.php

Potential Biomarker Panel for Early-Stage Pancreatic Cancer Identified--http://www.genengnews.com/news/bnitem.aspx?name=3696

Wednesday, June 11, 2008

027: Experimental drug makes the immune system revolt against cancer

One of the defining characteristics of cancer cells is their uncontrolled growth.
(Image Credit: Northwestern University)

Life Science Space (June 11, 2008)--A biotech company, founded by researchers from the University of Munich, has developed a fascinating way to make the immune system fight cancer.

On Thursday (June 5), Micromet Inc. announced that its experimental drug, MT103, had impressive results in a test upon seven Non-Hodgkin's Lymphoma patients. All of them had failed at least three conventional treatments, but showed signs of recovery after receiving doses of a two-headed antibody.

BiTE antibodies, or bispecific T cell engagers, are highly-engineered biological molecules with sticky ends. One side can cling to CD19, a protein found on cancerous B cells, and the other half can grab onto CD3, which is found on cytotoxic T cells. By momentarily drawing those cells together, the drug can coax the cytotoxic T cells into fighting the disease.

Training the immune system to fight cancer may be one of the best ways to keep it from coming back after several rounds of standard treatment. In most cases, surgery and radiation cannot get rid of every last cancer cell. Traditional chemotherapy may halt the growth of tumors, but it will not finish them off. Even after the best treatments, clusters of cancerous or pre-cancerous cells, called micrometastases, often drift around in the body and lodge themselves into vital organs.

To eliminate those lingering killers, many researchers have turned to cancer vaccines, which can convince the body to hunt down stray cancer cells and destroy them when they flare up. BiTE antibodies are another way to harness the defensive power of our immune systems.

When I spoke to Christian Itlin, CEO of Micromet, he said that many blockbuster cancer drugs are made from antibodies, and there is some evidence that they work by stirring up the immune system -- even though that is not how they were meant to operate. His company does intentionally what others have done accidentally -- making drugs that train the body to viciously attack cancer. In theory, their strategy could be used to combat many varieties of the deadly disease, but their treatment for lymphoma happens to be furthest along in the pipeline.

Since this was a very early trial, which was meant meant to assess the safety rather than effectiveness of the new drug, the good news should be a source of cautious optimism. Three more clinical trials of the BiTE antibody are starting in Germany. Two are for lymphoma. The newest one is meant to attack colorectal, gastrointestinal, and lung cancer.

---------------------------------------------------------
Adapted from article provided by wirescience @wired.com:
http://blog.wired.com/wiredscience/2008/06/experimental-dr.html
See also:

026: Scientists discover gene linked to adult-onset obesity

gene is the basic unit of heredity
(Image Credit: library.thinkquest.org)

Life Science Space (June 10, 2008)--Researchers at the University of Minnesota have discovered a gene that may provide a clue as to why obesity rates increase with age. The research was published today in the Proceedings of the National Academy of Sciences.

Researchers in the lab of Kevin Wickman, Ph.D., associate professor of pharmacology at the University of Minnesota Medical School, removed a single gene from mice as part of an ongoing study to understand how the brain controls heart function. While some cardiac deficiencies were detected in these mice, the researchers unexpectedly found that these mice exhibited a predisposition to adult-onset obesity. "This was not an outcome we expected, but now we have an animal model that may provide new insight into human obesity," said Wickman, co-author of the article.

By examining closely where this gene, termed Girk4, is expressed in the body, the researchers found particularly high levels in the hypothalamus, a brain region involved in regulating food intake and energy expenditure. Wickman speculated that disruption of normal function in the hypothalamus may underlie the obesity seen in the mutant mice, but he acknowledges that more research is needed to understand where and how this gene works, and consequently, why mice missing this gene develop obesity.

The age-dependence of the obesity seen in this mouse model mimics human obesity patterns, researchers said. Indeed, the likelihood of people developing obesity more than doubles between the ages of 20 and 60.

"This is a novel finding that may provide important new insight to the underlying cellular mechanisms that influence obesity," said Catherine Kotz, Ph.D., co-author of the article, scientist at the Minneapolis VA Medical Center and adjunct professor in the Department of Food Science and Nutrition at the University of Minnesota.

This research was funded by the University of Minnesota Graduate School, a pilot award from the Minnesota Obesity Consortium, and a grant from the National Institutes of Health. The research was conducted in collaboration with the Department of Veterans Affairs.

---------------------------------------------------------------------
Article provided by eurekalert: http://www.eurekalert.org/pub_releases/2008-06/uom-uom061008.php

See also:
Predisposition to late-onset obesity in GIRK4 knockout mice

Monday, June 9, 2008

024: Aggressive approach to diabetes proves harmful

Life Science Space (June 9, 2008)--Attacking blood sugar levels with high drug doses can be dangerous

Patients with type 2 diabetes, a high risk of cardiovascular disease, and who use aggressive measures to reduce their blood sugar levels could actually be shortening their lives, according to a large clinical trial. The results contradict the established theory that diabetics benefit from driving down their excessively high blood sugar levels as forcibly as possible.

The trial, part of ACCORD (Action to Control Cardiovascular Risk in Diabetes), made headlines earlier this year when this segment of the study was halted in February by a safety review board. The results are published today by The New England Journal of Medicine (1).

The results do not mean that diabetics should not work to keep their blood sugar under control, says cardiologist Harlan Krumholz of Yale Medical School in New Haven, Connecticut, but they do illustrate that taking extreme measures to lower blood sugar may not be warranted.

More than 10,000 type 2 diabetics, who either had cardiovascular disease or were at high risk for developing the condition, were enrolled in the trial. Roughly half used standard treatments to lower their blood sugar, and achieved an average level of ‘glycated haemoglobin’ – a measure of blood sugar – of 7.5%, which is thought to be acceptable, if higher than for a non-diabetic.

The other group used higher doses of the same drugs to lower their glycated haemoglobin, reaching levels of 6.4% over the course of a year. They maintained these low levels for just over three years.

Over the course of three and a half years, 257 people in the high-dosing group died compared with only 203 in the group that used standard doses.

Disturbing results

The finding shocked doctors, as they have been encouraged to lower blood sugar levels by any means possible. “The results are disturbing,” says Krumholz, who was not affiliated with the study. “This is a treatment strategy that people have been encouraged to adopt.”

Researchers have not yet worked out whether the fault lies with the methods used to lower blood sugar levels, or with the low blood sugar levels themselves. The American Diabetes Association recommends lowering glycated haemoglobin levels to below 7%; a non-diabetic would have levels of 5.5-6%, says study co-author Robert Byington of Wake Forest University in Winston-Salem, North Carolina.

Krumholz speculates that the negative effects may be a consequence of using higher doses of medications to lower the blood sugar levels. “As you start adding complex treatment regimens, you start offsetting the potential benefits with the added risk of adding medications,” he says.

Unclear cause

The drugs used by diabetics in the study included insulin, sulphonylurea and a class of drugs known as thiazolidinediones. That class includes rosiglitazone, marketed by GlaxoSmithKline as Avandia, which in a recent study was linked to an increased risk of cardiovascular problems. There is no clear link between rosiglitazone dosage and the increased death rate seen in the ACCORD study, says Byington. “We haven’t been able to identify any particular agent or treatment strategy that mediates the higher number of deaths,” says Byington.

Meanwhile another study, also published today (2), shows that intensive treatments to lower blood sugar levels can reduce the incidence a kidney disease commonly associated with diabetes. But the benefits were relatively minor, notes Krumholz.

The ACCORD results may encourage doctors to recommend lifestyle interventions – such as weight loss and exercise – as other options besides medication, Krumholz says.


References:
(1) The Action to Control Cardiovascular Risk in Diabetes Study Group N. Engl. J. Med. 358, 2545-2559 (2008).

(2) The ADVANCE Collaborative Group N. Engl. J. Med. 358, 2560-2572 (2008).

--------------------------------------------------------------------
Source: Nature News: http://www.nature.com/news/2008/080606/full/news.2008.879.html

023: Stripes key to nanoparticle drug delivery

Life Science Space (June 9, 2008)--In work that could at the same time impact the delivery of drugs and explain a biological mystery, MIT engineers have created the first synthetic nanoparticles that can penetrate a cell without poking a hole in its protective membrane and killing it.


MIT researchers have created 'striped' nanoparticles capable of entering a cell without rupturing it. In the background of this cartoon are cells that have taken up nanoparticles carrying fluorescent imaging agents (Image courtesy: Francesco Stellacci, Darrell Irvine and colleagues, MIT)

The key to their approach? Stripes.

The team found that gold nanoparticles coated with alternating bands of two different kinds of molecules can quickly pass into cells without harming them, while those randomly coated with the same materials cannot. The research was reported in a recent advance online publication of Nature Materials.

"We've created the first fully synthetic material that can pass through a cell membrane without rupturing it, and we've found that order on the nanometer scale is necessary to provide this property," said Francesco Stellacci, an associate professor in the Department of Materials Science and Engineering and co-leader of the work with Darrell Irvine, the Eugene Bell Career Development Associate Professor of Tissue Engineering.

In addition to the practical applications of such nanoparticles for drug delivery and more--the MIT team used them to deliver fluorescent imaging agents to cells--the tiny spheres could help explain how some biological materials such as peptides are able to enter cells.

"No one understands how these biologically derived cell-penetrating materials work," said Irvine. "So we could use the new particles to learn more about their biological counterparts. Could they be analogues of the biological system?"

When a cell membrane recognizes a foreign object such as a nanoparticle, it normally wraps around or "eats" it, encasing the object in a smaller bubble inside the cell that can eventually be excreted. Any drugs or other agents attached to the nanoparticle therefore never reach the main fluid section of the cell, or cytosol, where they could have an effect.


Such nanoparticles can also be "chaperoned" by biological molecules into the cytosol, but this too has drawbacks. Chaperones can work in some cells but not others, and carry one cargo but not another.
Hence the importance of the MIT work in developing nanoparticles that can directly penetrate the cell membrane, deliver their cargo to the cytosol, and do so without killing the cell.

Irvine compares the feat to a phenomenon kids can discover. "If you have a soap film and you poke it with a bubble wand, you'll pop it," he said. "But if you coat the bubble wand with soap before poking the film, it will pass through the film without popping it because it's coated with the same material." Stellacci notes that the coated nanoparticles have properties similar to the cell membrane--not identical--but the analogy is still apt.

Stellacci first reported the creation of the striped nanoparticles in a 2004 Nature Materials paper. At the time, "we noticed that they interacted with proteins in an interesting way," he said. "Could they also have interesting interactions with cells?" Four years later, he and his colleagues report a resounding "yes."

Stellacci and Irvine's coauthors are Ayush Verma, Oktay Uzun, Ying Hu and Suelin Chen of the Department of Materials Science and Engineering (MSE); Yuhua Hu of the Department of Chemical Engineering; Hee-Sun Han of the Department of Chemistry, and Nicky Watson of the Department of Biology.

Irvine has appointments in the Department of Biological Engineering and MSE, and is a member of the David H. Koch Institute for Integrative Cancer Research at MIT. He was recently named a Howard Hughes Medical Institute investigator.

The research was funded in part by the NSF, the NIH and the Packard Foundation

---------------------------------------------------------------------
Source:
MIT News: http://web.mit.edu/newsoffice/2008/nanocell-0609.html

Friday, June 6, 2008

018: Hay fever vaccine needs just four shots

Certain pollens are the principal cause of seasonal allergy
(Image Credit: A.D.A.M. Inc.)
Life Science Space (June 6, 2008)--Streaming eyes, runny nose and endless sneezing? Help might be on the way in the form of a hay-fever vaccine that works faster and involves far fewer injections than existing treatment regimens.

Hay fever and some other allergies are caused by an overactive immune response to pollen. Conventional treatments consist of a series of pollen injections that gradually increase in strength, eventually training the immune system to ignore pollen. It is a long, drawn-out process, requiring at least 100 shots spread over up to five years.

Meanwhile two vaccines against ragweed allergy developed by Dynavax Technologies of Berkeley, California, and Curalogic of Copenhagen in Denmark, require fewer injections but were recently abandoned because they worked no better than placebos.

Now, a low-hassle hay fever vaccine, requiring just four injections over four weeks, has been shown to have some effect. Although it is not dramatic, Tom Holdich of Allergy Therapeutics in Worthing, UK, which developed the vaccine, points out that it is the only one of its kind that works. Neil Kao, an allergy physician based in Greenville, South Carolina, agrees: "The size of symptom relief is small, but the convenience is very high."

The company gave 1028 volunteers in Europe and North America either its vaccine - Pollinex Quattro - or a placebo just before the start of the 2007 pollen season. During the four "peak" weeks, symptoms were on average 13 per cent less severe in vaccine recipients. One-third of volunteers recorded their symptoms between May and September, and for them the effect appeared to be doubled. The company will present the results on 8 June at the European Academy of Allergology and Clinical Immunology meeting in Barcelona, Spain.

As well as pollen, Pollinex contains monophosphoryl lipid A (MPL), which "retunes" the immune system by damping down the usual "Th2" reaction to pollen and encouraging the milder Th1 response. The vaccine works in a short time because its pollen protein has been modified both to sneak past the body's antibodies, allowing large doses to be given from the start, and to lodge in tissue rather than going directly into the bloodstream, prolonging its effect on the immune system.

Allergy Therapeutics hopes to apply for approval in Europe next year. In the US, the Food and Drug Administration must first review the safety of MPL, which is also present in a cervical cancer vaccine made by GlaxoSmithKline.
---------------------------------------------------------------------
Source: New Scientist magazine, 05 June 2008, page 12
See also:

Allergy Therapeutics--

http://www.allergytherapeutics.com/POLLINEX%20Quattro%20.aspx

http://www.allergytherapeutics.com/G301%20results.aspx

PubMed--

http://www.ncbi.nlm.nih.gov/pubmed/17299813

017: A Little Hope for Cancer Treatment

A sample of cancer cells infused with the nanoimpellers fills the bottom of a test tube in Dr. Fuyuhiko Tamanoi's lab in the Department of Microbiology, Immunology and Molecular Genetics at UCLA.
(Image Credit: Dave Bullock/Wired.com)


Life Science Space (June 6, 2008)--UCLA scientists have developed a process for targeting cancer cells that could eliminate some of the worst side effects of chemotherapy.

The new technique deploys nanoscale, light-activated containers filled with cancer-fighting drugs throughout the body. These containers release the drugs only when targeted by a special laser, allowing scientists to confine treatment only to desired areas of the body.

Normally in chemotherapy, the drugs are delivered to the whole body and attack healthy cells as well as the cancerous ones, which can be devastating to cancer patients. In a couple of years, these new nanomachines, called nanoimpellers, could help eliminate cancer in specific areas of a patient while the unused drugs pass through the body without affecting healthy tissue.


Figure A shows how cancer cells quickly die after absorbing the nanoimpellers and being exposed to the precisely calibrated laser (413 nm).

Figure B shows how cells that are exposed to the light without the nanoimpellers, or with nanoimpellers but with no anti-cancer drug, end up living a happy cancerous life.

Figure C shows untreated cells and cells infused with unactivated nanoimpellers in the dark.

--------------------------------------------------------------------

Article Linked: http://www.wired.com/science/discoveries/multimedia/2008/06/gallery_nanocancer

See also:

Thursday, June 5, 2008

016: Human stem cells used to cure brain disorder

Success in mice could be a breakthrough for disorders such as multiple sclerosis.

Human donor cells (red) spread through the mouse brains and trigger their repair.

(Image Credit:Windrem et al.)

Life Science Space (June 5, 2008)--Human stem cells have been used to correct abnormal brain development in mice with fatal brain disorders, offering hope for treating a range of neurological disorders including some deadly childhood genetic diseases.

Those behind the new treatment hope that human clinical trials could be just a few years away.

The treatment uses human glial progenitor cells — cells that can differentiate into the glial cells that, among other things, make up myelin. Myelin, a protein that insulates the long 'arms' of nerve cells, called axons, helps the conduction of neural signals throughout the nervous system.

A team led by Steven Goldman, at the University of Rochester in New York, took the progenitor cells from white matter in the fetal human brain and injected them into the spinal cords of mutant shiverer mice shortly after their birth.

The mice, which shiver and shake as their name suggests, have severe neurological defects caused by a genetic mutation that stops them producing myelin. Without myelin, neural signals get stuck, causing potentially fatal disease.

“There’s no way we’d be able to conduct a [neural] signal very far if it weren’t for myelin,” Goldman explains. As they develop, shiverer mice become unable to walk forwards, have increasing numbers of seizures, and typically die at just 18–21 weeks of age.

Debilitating diseases

In humans, myelin losses also cause serious diseases. Multiple sclerosis is characterised by myelin loss in some areas of the brain. Some rare childhood diseases are also caused by an inability to produce myelin. One such example is adrenoleukodystrophy, a disease whose profile was raised by the film Lorenzo’s Oil, which tells the story Lorenzo Odone and his family’s battle to find a cure for his condition. Odone died last week, aged 30. “These are awful, awful diseases,” says Goldman.

Goldman has spent four years perfecting a technique to implant human glial progenitor cells into the nervous system of mice. In the experiment, published in the journal Cell Stem Cell (Windrem, M. S. et al. Cell Stem Cell 2, 553-565 (2008), Goldman used five injection sites to allow the human stem cells to penetrate the entire nervous system of the baby mice.

The researchers knew that if the mouse immune system was suppressed, preventing rejection, the mice would have a better chance of survival. So Goldman used mice that were a cross between shiverer mice and mice genetically modified to have their immune system suppressed.

The team treated 26 of these mice with 300,000 human glial progenitor cells each, 29 with a set of control injections, and left 59 untreated. All the mice deteriorated in health in the first 130 days, as is usual for shiverer mice, and by 150 days all of the control and untreated mice had died. But six of the stem-cell-treated mice survived for longer than 130 days, and four of those went on to live for 14 months, at which time they were sacrificed for analysis.

Transformation

The mice that improved showed impressive myelin growth at sites where the new cells had been implanted. “Myelination was much more than anything we’d seen,” says Goldman. The new myelin was also structurally normal.

The mice did better than just survive — as the myelin grew, the mice began to lose signs of being shiverers. They gained normal brain activity, no longer had seizures and lost much of the shakiness. “As they live longer, they slowly but surely get better,” says Goldman.

He thinks that if he can get the mice through the sick stage of their early life, perhaps by giving them anti-convulsants to stop the seizures that cause so much damage, he can improve his rescue rate.The breakthrough is “stunning”, says Ian Duncan, who studies myelin at the University of Wisconsin-Madison. The work will have greatest relevance in treating congenital childhood diseases, he says, although he warns that a practical therapy is still some way away. ”This is a therapy for the future,” he says.

“This is a good proof of principle,” says Goldman. He is optimistic that once his methods meet with the approval of the US Food and Drug Administration, clinical trials in humans may only be a few years away. There is nothing in the biology that needs to be clarified, he says: “The questions become practical.”

--------------------------------------------------------------------

Article linked: http://www.nature.com/news/2008/080604/full/news.2008.875.html

See also @
Stem cells can cure nerve disease
http://ls-space.blogspot.com/2008/06/012-stem-cells-halt-nerve-disease.html

Wednesday, June 4, 2008

013: Stem cells can cure nerve disease

Life Science Space (June 4, 2008)-- An injection of stem cells has been used to cure mice with a normally fatal nervous system condition.

The therapy which helped repair faulty nerve wiring raises hopes of treatments for children with rare and deadly nervous leukodystrophy disorders.

A UK expert said human treatments were still some way off - but potentially the technique could be used to treat conditions such as multiple sclerosis.

The US study features in the journal Cell: Stem Cell.

The scientists from the University of Rochester Medical Center believe it may be the first time that this type of "shiverer" mouse has been cured.

Its genetic makeup means that its nerve cells do not have enough myelin, a fatty coating which acts like the sheath on an electrical wire.

Without it, nerve signals do not travel properly from cell to cell, causing the trademark shaking and wobbling symptoms, and normally death within four months.

There are dozens of rare human disorders which involve genetic myelin-related faults in the nervous system, most of which are fatal in childhood or young adulthood.

One of the most well-known of these affected Lorenzo Odone, who died last week after decades battling adrenoleukodystrophy.

:: Surviving minority

The US team did not use "true" stem cells, which have the ability to turn into any cell in the body, but precursor stem cells, which can become one of a limited number of cell types.

The green shows neurons in the brain of a mouse that have been remyelinated as a result of stem cell research. (Image Credit: University of Rochester)

The "glial cells" used here can become among other things, oligdendrocytes, the cells which produce the myelin sheath.

The cells were injected in different places in the central nervous system in a bid to see if this could make any difference to the overall symptoms.

For most, it made none, with three-quarters of the 26 mice injected dying around the same time as mice who had received no treatment.

However, for six mice, the difference was stark - in just two months, the cells had spread around, multiplying, and covering nerve cells in the brain and spinal cord, and producing myelin to coat them.

Two of the mice lived longer than usual, but the other four were still alive a year later, free from virtually all symptoms.

:: 'Awful disease'

Professor Steven Goldman, who led the study, said: "We kept expecting them to die, but not only did they not die, they improved day by day.

"It's extremely exciting to think about not only treating but actually curing a disease, particularly an awful disease that affects children.

Professor David Attwell, from University College London, said the study represented an "important proof of principle" that transplantation of these "precursor" cells could help restore myelin not only within people with leukodystrophies, but in theory within those affected by other conditions involving loss of myelin, such as multiple sclerosis, cerebral palsy and spinal cord injury.

However, he said: "The work is still a long way from being applied in humans, and the paper raises several issues which could affect the chances of that happening.

"Only a small fraction of the mice were cured, and it is unclear why." He said that other potential hurdles were whether within humans, defective myelin-producing cells would be as readily replaced by the new transplanted in versions, and whether, as in the mice, the immune system would have to be suppressed prior to treatment.


---------------------------------------------------------------------


See also:

Monday, June 2, 2008

011: Stem Cells Work Medical Magic

What stem cell researchers are really studying is how your body was made and how to do it all over again. Embryonic stem cells (or the newer induced-without-embryos variety) can travel down any of the paths below to become skin, heart, brain and other body parts. So-called adult stem cells are stuck in the middle, able to become certain types of cells but not others. In nature, cells don’t travel backward on these developmental paths; stem cell researchers hope to treat disease by getting them to do just that.


>> Paths To A Person:

Image Credit: Forbes.com

>> Stem Cells Work Medical Magic

:: Make Better Antidepressants
Turning on stem cells in the brain could create the next generation of antidepressants. The idea that drugs like Prozac and Zoloft work by boosting the chemical serotonin is so widely known that drug companies use it in their ads. But the drugs' most important function may be to spur the growth of new neurons in the brain--blocking the growth of new brain cells in mice renders Prozac and other antidepressants ineffective. BrainCells Inc. is working on creating mood-elevating drugs that work by causing brain stem cells to grow.

:: Augment Breasts
Cytori Therapeutics, a tiny biotech firm traded on the Nasdaq, has developed a medical device that spots stem cells in fat. The company hopes these might heal lots of different body parts, including the heart. But the first use is breast reconstruction after a partial mastectomy. The idea is that the fat stem cells can be made to regrow tissue in ways fat cells can't. Right now, the device is marketed in Europe. Cytori is conducting clinical trials to test it for breast augmentation that could lead to U.S. approval.

:: Alleviate Down Syndrome
Down syndrome occurs when a person has an extra copy of his or her 21st chromosome. But what exactly goes wrong? A potential culprit is a misfire among a group of signaling proteins that tell stem cells in an embryo how to create a brain. Stanford's Philip Beachy already knew "hedgehog" misfires (the so-called hedgehog genes are essential to embryonic development) could lead to sheep with one eye or with underdeveloped brains. Down syndrome also seems to cause a hedgehog misfire. Fate Therapeutics, which Beachy co-founded, is looking into whether a drug that boosts hedgehog-gene activity could limit the damage from Down Syndrome if it were given to newborns.

:: Treat Cancer
It may be aberrant stem cells in tumors are what make cancer so malignant. In 2003, Stanford oncologist Michael Clarke shocked other scientists by isolating breast cancer stem cells. They formed only 5% of the tumor, but just a couple hundred of them could cause a new tumor in a mouse. Implanting tens of thousands of other breast cancer cells did nothing. The upshot is that the problem with current cancer treatments may be that they kill regular tumor cells but don't kill the stem cells that allow tumors to keep growing. GlaxoSmithKline will pay OncoMed Pharmaceuticals, a company Clarke founded, up to $1.4 billion for developing drugs that kill cancer stem cells.

:: Slow Parkinson's Disease
It is only because of the existence of human embryonic stem cells that researchers can directly study the neurons dying off in Parkinson's. It could be that, in 20 years, almost every medical researcher is going to use embryonic stem cells as basic tools.

Another approach comes from the laboratory of Wisconsin researcher Clive Svendsen. He is creating genetically engineered fetal cells that would act like drug factories in the brain, churning out a growth factor that could prevent brain cells from dying.

:: Make Alzheimer's Drugs
Last year (2005), scientists in the U.S. and Japan discovered a way to create cells that act like embryonic stem cells but without ever using embryos--instead, they use genetically modified viruses to transform adult human cells into embryolike stem cells by activating only four genes.

University of California, San Diego, researcher Lawrence Goldstein is using these so-called "induced pluripotent" stem cells to make neurons that are "genetically identical" to those of Alzheimer's patients. He is collecting 50 skin samples from Alzheimer's patients in order to hunt for new drugs.

:: Create Drugs For Lou Gehrig's Disease
New technologies that create embryo-like stem cells without embryos could be a boon for drug research. Case in point: amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig's disease, which is caused by the sudden death of motor neurons in middle age. First, scientists want to find toxins that kill neurons destined to get ALS, but leave normal neurons alive. Then they hope to find potential drugs that keep the ALS neurons from dying. Such medicines might prove to be effective treatments for the disease.

:: Cure Type 1 Diabetes
Patients with Type 1 diabetes must take four or more shots of insulin a day because their insulin-producing cells have been killed by a haywire immune system.

Novocell, a San Diego biotech, plans to turn embryonic stem cells into these missing insulin producers and inject them into the bodies of diabetics to put their disease into remission. Medical giants J&J and Becton Dickinson are backing the firm. The technique has been successful in mice, but it will take at least three years before Novocell's treatment is ready to be tested in humans.

:: Treat Tay-Sachs Disease
Tay-Sachs disease is a fatal genetic disorder in which a fatty substance builds up in the cells of the brain, eventually killing them.

The problem is that key enzymes that break this fatty substance down are missing. Evan Snyder at the Burnham Institute for Medical Research in La Jolla, Calif., hopes healthy stem cells can treat the disease by replacing these missing enzymes. When his team implanted stem cells into mice with a disease similar to Tay-Sachs, the animals lived at least 70% longer. A human trial could begin next year.


---------------------------------------------------------------------

Source:

http://www.forbes.com/2008/05/28/stem-cells-biz-healthcare-cx_mh_0528medtech_pathschart.html